COMPANY

Progentos Therapeutics

Keywords: neurology multiple sclerosis regenerative medicine PRO-1562

Location: Cambridge, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Timeline

2026-10 Trial start 1: A Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relapsing Multiple Sclerosis source ↗

2028-12 (ESTIMATED) · 1 · A Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relapsing Multiple Sclerosis · NCT07826689

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07826689	A Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relapsing Multiple Sclerosis	1	Recruiting	2026-10	2028-12 (estimated)